
    in most sites had difficult to recruitting subjects.
  
['renal cell carcinoma']
['sunitinib malate']

        Inclusion Criteria:

          -  Advanced renal cell carcinoma with histology confirmation

          -  Grade III/IV AEs happen during first cycle of sunitinib 50mg/day 4 weeks on followed
             by 2 weeks of rest

          -  ECOG performance status 0 or 1

          -  Appropriate vital organ functions

        Exclusion Criteria:

          -  Prior systemic treatment of mRCC

          -  Patients treated with any neoadjuvant or adjuvant systemic therapy

          -  Major surgery <4 weeks or radiation therapy <2 weeks of starting the study treatment.
             Prior palliative radiotherapy to metastatic lesion(s) is permitted, provided there is
             at least one measurable lesion that has not been irradiated

          -  Pregnant

          -  Allergic history to sunitinib
      